Embecta Faces Shareholder Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Allegations: A shareholder class action lawsuit has been filed against Embecta Corp., alleging that the company failed to disclose segment weakness in the U.S. pen needle market, which could disrupt its revenue guidance for Q2 2026, leading to investor losses.
- Investor Rights: Investors who purchased Embecta shares between November 25, 2025, and May 4, 2026, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and seek compensation.
- Legal Representation: Holzer & Holzer, established in 2000, focuses on vigorous representation of shareholders and investors, having recovered hundreds of millions of dollars for those affected by fraud and corporate misconduct.
- Lawsuit Deadline: Investors must apply to the court to be appointed lead plaintiff by August 17, 2026, to ensure their rights are protected in the ongoing litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMBC
About EMBC
Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lawsuit Background: A securities class action lawsuit has been filed in the U.S. District Court for New Jersey on behalf of all investors who acquired Embecta Corp. securities between November 25, 2025, and May 4, 2026, alleging the company failed to disclose misleading and unattainable guidance.
- Performance Miss: Embecta revealed a revenue decline of over 14% in its Q2 2026 results, significantly worse than the previously expected flat to a 2% decline, leading to a sharp drop in investor confidence regarding the company's future performance.
- Stock Price Plunge: On May 5, 2026, Embecta's stock price plummeted from $9.25 per share on May 4 to $3.90 per share, marking a dramatic decline of over 57.8% in a single day, reflecting the market's strong disappointment with the company's performance.
- Investor Reaction: The swift reaction from investors and analysts to Embecta's disappointing results, coupled with the initiation of the class action lawsuit, indicates significant dissatisfaction with the company's management, which could adversely affect future investor confidence and the company's reputation.
See More
- Lawsuit Allegations: A shareholder class action lawsuit has been filed against Embecta Corp., alleging that the company failed to disclose segment weakness in the U.S. pen needle market, which could disrupt its revenue guidance for Q2 2026, leading to investor losses.
- Investor Rights: Investors who purchased Embecta shares between November 25, 2025, and May 4, 2026, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and seek compensation.
- Legal Representation: Holzer & Holzer, established in 2000, focuses on vigorous representation of shareholders and investors, having recovered hundreds of millions of dollars for those affected by fraud and corporate misconduct.
- Lawsuit Deadline: Investors must apply to the court to be appointed lead plaintiff by August 17, 2026, to ensure their rights are protected in the ongoing litigation.
See More
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the period from November 25, 2025, to May 4, 2026.
- False Statements: The complaint alleges that Embecta made false and misleading statements, as the company was aware of challenges in the pen needle market but misled investors into believing its fiscal guidance was based on reliable data, leading to significant investor deception.
- Investor Participation: Shareholders who purchased EMBC shares during the class period are encouraged to contact DJS Law Group regarding potential lead plaintiff appointments, noting that being appointed as lead plaintiff is not necessary to participate in any recovery.
- Legal Service Advantage: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
- Lawsuit Initiation: On June 17, 2026, Levi & Korsinsky announced a class action lawsuit against Embecta Corp for shareholders who purchased stock between November 25, 2025, and May 4, 2026, underlining significant investor concerns regarding the company's financial health.
- False Statements: The lawsuit alleges that Embecta misled investors by providing overly optimistic financial guidance while concealing the true state of its performance, particularly in light of poor results in its pen needle business, which has eroded market confidence.
- Performance Decline: Embecta's Q2 2026 fiscal results revealed a revenue drop of over 14%, significantly worse than the guidance of flat to a 2% decline, indicating weakness in the U.S. market, particularly due to poor pen needle sales.
- Stock Price Plunge: Following the news on May 5, 2026, Embecta's stock price plummeted from $9.25 per share on May 4 to $3.90 per share, a staggering decline of over 57.8% in a single day, reflecting extreme investor disappointment and substantial losses for shareholders.
See More
- Executive Appointment: Embecta Corp. announced the appointment of Nimish Muzumdar as President for North America effective June 15, 2026, where he will lead the commercial teams in the U.S. and Canada, executing long-term growth strategies that are expected to drive the company's expansion into chronic care markets.
- Extensive Experience: Muzumdar previously served as Senior Vice President at Sandoz, where he successfully returned its $1 billion division to sustained profitable growth, showcasing his exceptional capabilities in the highly competitive generic drugs industry, which will provide strong support for Embecta's transformation.
- Equity Incentive: As an inducement grant for his employment, Muzumdar received 638,978 time-vested restricted stock units, which are set to vest over three years, aimed at attracting his long-term commitment and driving the company's growth.
- Strategic Transformation: Embecta is transitioning from a company focused on insulin delivery to a broad-based medical supplies company, and Muzumdar's appointment will aid in expanding the product portfolio to address chronic conditions such as obesity and diabetes, thereby enhancing market competitiveness.
See More
- Investor Meeting Schedule: Embecta Corp. will host one-on-one investor meetings on June 3, 2026, at the Marriott Marquis in New York City, aimed at enhancing direct communication with investors and boosting market confidence.
- Diabetes Tech Summit: The company will hold a fireside session on June 5, 2026, at the Westin in New Orleans, expected to attract industry attention and showcase its innovative solutions in diabetes management.
- Goldman Sachs Global Healthcare Conference: Embecta plans to conduct one-on-one investor meetings on June 9, 2026, at the Loews Hotel in Miami, furthering relationships with potential investors and strengthening its market position in medical supplies.
- Truist Securities MedTech Conference: The company will host one-on-one investor meetings on June 16, 2026, at the Boston Harbor Hotel, showcasing its latest advancements in medical technology to attract more investor interest in its business transformation.
See More






